Interestingly, patients with low NSUN5 expression had better clinical outcomes in all grades of gliomas, possibly because this epigenetic silencing increased the sensitivity of glioma to specific treatments.[28,29] In our study, NSUN5 expression was also shown to be a prognostic risk factor for GBM. Here, NSUN5 is linked to glioma.